, Volume 24, Issue 6, pp 351-354
Date: 23 Sep 2003

Therapy with infliximab decreases the CD4+CD28− T cell compartment in peripheral blood in patients with rheumatoid arthritis

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Chronic inflammatory syndromes such as rheumatoid arthritis (RA) are associated with high frequencies of CD4+CD28− T cells. The number of these cells is genetically determined and may also be a consequence of chronic exposure to tumor necrosis factor-alpha (TNFα). The aim of this study was to examine whether the reported efficacy of anti-TNFα therapy in RA involves a resurgence of T cell populations that re-express CD28. After 36-week therapy with infliximab, a significant decrease in CD4+CD28− T cells in RA patients was observed in comparison with baseline. The results suggest that TNFα-neutralizing therapy may restore T cell homeostasis and reduce expansion of the CD28− T cells, which are cytotoxic and may contribute to organ manifestations in RA.